Combination strategies to maximize the benefits of cancer immunotherapy

HLA class I-specific inhibitory receptors in human T lymphocytes: Interleukin 15-induced expression of CD94/NKG2A in superantigen- or alloantigen-activated CD8 + T cells

Mingari, M. C., Ponte, M., Bertone, S., Schiavetti, F., Vitale, C., Bellomo, R., Moretta, A., & Moretta, L. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.3.1172 · Cited by 241

Radiation-induced effects and the immune system in cancer

Kaur, P., & Asea, A. A. A. (2012) · Frontiers in Oncology · doi:10.3389/fonc.2012.00191 · Cited by 233

A First-in-Human Study and Biomarker Analysis of NKTR-214, a Novel IL2Rβγ-Biased Cytokine, in Patients with Advanced or Metastatic Solid Tumors.

(2019) · doi:10.1158/2159-8290.cd-18-1495 · Cited by 231

Optimized fractionated radiotherapy with anti-PD-L1 and anti-TIGIT: a promising new combination

Grapin, M., Richard, C., Limagne, E., Boidot, R., Morgand, V., Bertaut, A., Dérangère, V., Laurent, P.-A., Thibaudin, M., Fumet, J.-D., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0634-9 · Cited by 230

Armed Oncolytic Adenovirus–Expressing PD-L1 Mini-Body Enhances Antitumor Effects of Chimeric Antigen Receptor T Cells in Solid Tumors

Tanoue, K., Shaw, A. R., Watanabe, N., Porter, C., Rana, B., Gottschalk, S. M., Brenner, M. K., & Suzuki, M. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-1577 · Cited by 225

Vaccination during myeloid cell depletion by cancer chemotherapy fosters robust T cell responses

Welters, M. J. P., van der Sluis, T. C., van Meir, H., Loof, N. M., van Ham, V. J., van Duikeren, S., Santegoets, S. J. A. M., Arens, R., de Kam, M. L., Cohen, A. F., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad8307 · Cited by 216

Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Second-Line Treatment of Patients With NSCLC: Results From an Expansion Cohort of a Phase 1 Trial

Paz-Ares, L. G., Kim, T. M., Vicente, D., Felip, E., Lee, D. H., Lee, K. H., Lin, C., Flor, M. J., Nicola, M. D., Alvarez, R. M., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.03.003 · Cited by 208

Inhibitory leukocyte immunoglobulin-like receptors: Immune checkpoint proteins and tumor sustaining factors

Kang, X., Kim, J., Deng, M., John, S., Chen, H., Wu, G., Phan, H., & Zhang, C. C. (2015) · Cell Cycle · doi:10.1080/15384101.2015.1121324 · Cited by 207

Hypoxia-Driven Immunosuppressive Metabolites in the Tumor Microenvironment: New Approaches for Combinational Immunotherapy

Li, Y., Patel, S. P., Roszik, J., & Qin, Y. W. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01591 · Cited by 203

M7824, a novel bifunctional anti-PD-L1/TGFβ Trap fusion protein, promotes anti-tumor efficacy as monotherapy and in combination with vaccine

Knudson, K. M., Hicks, K. C., Luo, X., Chen, J.-Q., Schlom, J., & Gameiro, S. R. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1426519 · Cited by 195

Phase I/II Trial of Carboplatin and Paclitaxel Chemotherapy in Combination with Intravenous Oncolytic Reovirus in Patients with Advanced Malignancies

Karapanagiotou, E. M., Roulstone, V., Twigger, K. R., Ball, M., Tanay, M. A., Nutting, C. M., Newbold, K. L., Gore, M. E., Larkin, J., Syrigos, K. N., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2181 · Cited by 193

Epigenetics and immunotherapy: The current state of play

Dunn, J., & Rao, S. (2017) · Molecular Immunology · doi:10.1016/j.molimm.2017.04.012 · Cited by 192

TRUCKS, the fourth‐generation CAR T cells: Current developments and clinical translation

Chmielewski, M. M., & Abken, H. (2020) · Advances in Cell and Gene Therapy · doi:10.1002/acg2.84 · Cited by 186

Pembrolizumab plus GX-188E therapeutic DNA vaccine in patients with HPV-16-positive or HPV-18-positive advanced cervical cancer: interim results of a single-arm, phase 2 trial

Youn, J. W., Hur, S. Y., Woo, J. W., Kim, Y., Lim, M. C., Park, S., Seo, S. S., No, J. H., Kim, B., Lee, J. K., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30486-1 · Cited by 180

The advent of oncolytic virotherapy in oncology: The Rigvir® story

Alberts, P., Tilgase, A., Rasa, A., Bandere, K., & Venskus, D. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.08.042 · Cited by 178

Toward Precision Radiotherapy for Use with Immune Checkpoint Blockers

Vanpouille‐Box, C., Formenti, S. C., & Demaria, S. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0037 · Cited by 177

Constitutive IDO1 Expression in Human Tumors Is Driven by Cyclooxygenase-2 and Mediates Intrinsic Immune Resistance

Hennequart, M., Pilotte, L., Canè, S., Hoffmann, D., Stroobant, V., Plaen, E. D., & den Eynde, B. J. V. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0400 · Cited by 176

Intra-tumoral delivery of CXCL11 via a vaccinia virus, but not by modified T cells, enhances the efficacy of adoptive T cell therapy and vaccines

Moon, E. K., Wang, L.-C. S., Bekdache, K., Lynn, R. C., Lo, A., Thorne, S. H., & Albelda, S. M. (2018) · OncoImmunology · doi:10.1080/2162402x.2017.1395997 · Cited by 174

Targeted delivery of oligonucleotides into tumor-associated macrophages for cancer immunotherapy

Huang, Z. D., Zhang, Z., Jiang, Y., Zhang, D., Chen, J., Dong, L., & Zhang, J. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.11.013 · Cited by 172

Chimeric antigen receptor-engineered natural killer cells for cancer immunotherapy

Yilmaz, A., Cui, H., Caligiuri, M. A., & Yu, J. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00998-9 · Cited by 171

Cutting Edge: Autocrine TGF-β Sustains Default Tolerogenesis by IDO-Competent Dendritic Cells

Belladonna, M. L., Volpi, C., Bianchi, R., Vacca, C., Orabona, C., Pallotta, M. T., Boon, L., Gizzi, S., Fioretti, M. C., Grohmann, U., et al. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.8.5194 · Cited by 169

VEGF directly suppresses activation of T cells from ovarian cancer patients and healthy individuals via VEGF receptor Type 2

Ziogas, A. C., Gavalas, N. G., Tsiatas, M. L., Tsitsilonis, O., Politi, E., Terpos, E., Rodolakis, A., Vlachos, G. D., Thomakos, N., Haidopoulos, D. A., et al. (2011) · International Journal of Cancer · doi:10.1002/ijc.26094 · Cited by 168

Role of CD47 in Hematological Malignancies

Eladl, E., Tremblay‐LeMay, R., Rastgoo, N., Musani, R., Chen, W.-M., Liu, A., & Chang, H. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00930-1 · Cited by 163

Role of Radiation Therapy in Modulation of the Tumor Stroma and Microenvironment

Menon, H., Ramapriyan, R., Cushman, T. R., Verma, V., Kim, H. H., Schoenhals, J. E., Atalar, S. C., Selek, U., Chun, S. G., Chang, J. Y., et al. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00193 · Cited by 160

Interdisciplinary Critique of Sipuleucel-T as Immunotherapy in Castration-Resistant Prostate Cancer

Huber, M. L., Haynes, L., Parker, C. C., & Iversen, P. (2012) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djr514 · Cited by 158

Checkpoint Inhibitors Augment CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy in Relapsed B-Cell Acute Lymphoblastic Leukemia

Li, A. M., Hucks, G., DiNofia, A. M., Seif, A. E., Teachey, D. T., Baniewicz, D., Callahan, C. A., Fasano, C., McBride, B., Gonzalez, V. E., et al. (2018) · Blood · doi:10.1182/blood-2018-99-112572 · Cited by 156

Modeling the receptor pharmacology, pharmacokinetics, and pharmacodynamics of NKTR-214, a kinetically-controlled interleukin-2 (IL2) receptor agonist for cancer immunotherapy

Charych, D. H., Khalili, S., Dixit, V., Kirk, P. B., Chang, T., Langowski, J. L., Rubas, W., Doberstein, S. K., Eldon, M. A., Hoch, U., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0179431 · Cited by 155

Oncolytic Adenoviral Delivery of an EGFR-Targeting T-cell Engager Improves Antitumor Efficacy

Fajardo, C. A., Guedan, S., Rojas, L. A., Moreno, R., Arias-Badia, M., de Sostoa, J., June, C. H., & Alemany, R. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-1708 · Cited by 152

Selective inhibition of TGF-β1 produced by GARP-expressing Tregs overcomes resistance to PD-1/PD-L1 blockade in cancer

de Streel, G., Bertrand, C., Chalon, N., Liénart, S., Bricard, O., Lecomte, S., Devreux, J., Gaignage, M., Boeck, G. D., Mariën, L., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17811-3 · Cited by 151

Blockade of surface-bound TGF-β on regulatory T cells abrogates suppression of effector T cell function in the tumor microenvironment

Budhu, S., Schaer, D., Li, Y., Toledo‐Crow, R., Panageas, K. S., Yang, X., Zhong, H., Houghton, A. N., Silverstein, S. C., Merghoub, T., et al. (2017) · Science Signaling · doi:10.1126/scisignal.aak9702 · Cited by 148

Transforming Growth Factor β and Cyclosporin A Inhibit the Inducible Activity of the Interleukin-2 Gene in T Cells Through a Noncanonical Octamer-Binding Site

Brabletz, T., Pfeuffer, I., Schorr, E., Siebelt, F., Wirth, T., & Serfling, E. (1993) · Molecular and Cellular Biology · doi:10.1128/mcb.13.2.1155-1162.1993 · Cited by 146

The Promise of Combining Radiation Therapy With Immunotherapy

Jagodinsky, J. C., Harari, P. M., & Morris, Z. S. (2020) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2020.04.023 · Cited by 145

Anti-tumour synergy of cytotoxic chemotherapy and anti-CD40 plus CpG-ODN immunotherapy through repolarization of tumour-associated macrophages

Buhtoiarov, I. N., Sondel, P. M., Wigginton, J. M., Buhtoiarova, T. N., Yanke, E. M., Mahvi, D. A., & Rakhmilevich, A. L. (2010) · Immunology · doi:10.1111/j.1365-2567.2010.03357.x · Cited by 143

5-aza-2'-deoxycytidine-induced expression of functional cancer testis antigens in human renal cell carcinoma: immunotherapeutic implications.

Coral, S., Sigalotti, L., Altomonte, M., Engelsberg, A., Colizzi, F., Cattarossi, I., Maraskovsky, E., Jäger, E., Seliger, B., & Maio, M. (2002) · PubMed · Cited by 143

The role of IL-6 in the radiation response of prostate cancer

Wu, C., Chen, M., Chen, W., & Hsieh, C. (2013) · Radiation Oncology · doi:10.1186/1748-717x-8-159 · Cited by 141

Thrombin contributes to cancer immune evasion via proteolysis of platelet-bound GARP to activate LTGF-β

Metelli, A., Wu, B. X., Riesenberg, B., Guglietta, S., Huck, J. D., Mills, C., Li, A., Rachidi, S., Krieg, C., Rubinstein, M. P., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aay4860 · Cited by 139

Correction: Consensus guidelines for the definition, detection and interpretation of immunogenic cell death

Galluzzi, L., Vitale, I., Warren, S., Adjemian, S., Agostinis, P., Buqué, A., Chan, T. A.-T., Coukos, G., Demaria, S., Deutsch, E., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000337corr1 · Cited by 139

An intact immune system is required for the anticancer activities of histone deacetylase inhibitors

West, A. C., Mattarollo, S. R., Shortt, J., Cluse, L. A., Christiansen, A. J., Smyth, M. J., & Johnstone, R. W. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-0890 · Cited by 137

Papillary Carcinoma of the Thyroid

Scarpino, S., Stoppacciaro, A., Ballerini, F., Marchesi, M., Prat, M., Stella, M. C., Sozzani, S., Allavena, P., Mantovani, A., & Ruco, L. (2000) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)64951-6 · Cited by 135

Strong vaccine responses during chemotherapy are associated with prolonged cancer survival

Melief, C. J. M., Welters, M. J. P., Vergote, I., Kroep, J. R., Kenter, G. G., Ottevanger, P. B., Tjalma, W. A. A., Denys, H., van Poelgeest, M. I. E., Nijman, H. W., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aaz8235 · Cited by 134

Biomaterials for enhancing anti-cancer immunity

Koshy, S. T., & Mooney, D. J. (2016) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2016.02.001 · Cited by 132

Delivery methods to increase cellular uptake and immunogenicity of DNA vaccines

Jorritsma, S. H. T., Gowans, E. J., Grubor‐Bauk, B., & Wijesundara, D. K. (2016) · Vaccine · doi:10.1016/j.vaccine.2016.09.062 · Cited by 132

Functional Up-regulation of Human Leukocyte Antigen Class I Antigens Expression by 5-aza-2′-deoxycytidine in Cutaneous Melanoma: Immunotherapeutic Implications

Fonsatti, E., Nicolay, H. J. M., Sigalotti, L., Calabrò, L., Pezzani, L., Colizzi, F., Altomonte, M., Guidoboni, M., Marincola, F. M., & Maio, M. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-3091 · Cited by 131

Oncolytic adenovirus expressing bispecific antibody targets T‐cell cytotoxicity in cancer biopsies

Freedman, J. D., Hagel, J., Scott, E. M., Psallidas, I., Gupta, A., Spiers, L., Miller, P. F., Kanellakis, N. I., Ashfield, R., Fisher, K. D., et al. (2017) · EMBO Molecular Medicine · doi:10.15252/emmm.201707567 · Cited by 127

CXC Chemokine Ligand 9/Monokine Induced by IFN-γ Production by Tumor Cells Is Critical for T Cell-Mediated Suppression of Cutaneous Tumors

Gorbachev, A. V., Kobayashi, H., Kudo, D., Tannenbaum, C. S., Finke, J. H., Shu, S., Farber, J. M., & Fairchild, R. L. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.4.2278 · Cited by 126

CD47 Signaling Regulates the Immunosuppressive Activity of VEGF in T Cells

Kaur, S., Chang, T., SINGH, S. P., Lim, L., Mannan, P., Garfield, S. H., Pendrak, M. L., Soto‐Pantoja, D. R., Rosenberg, A. Z., Jin, S., et al. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1303116 · Cited by 126

Blocking IL1 Beta Promotes Tumor Regression and Remodeling of the Myeloid Compartment in a Renal Cell Carcinoma Model: Multidimensional Analyses

Aggen, D. H., Ager, C. R., Obradović, A., Chowdhury, N., Ghasemzadeh, A., Mao, W., Chaimowitz, M. G., Bujanda, Z. A. L., Spina, C. S., Hawley, J. E., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1610 · Cited by 126

Ibrutinib modulates the immunosuppressive CLL microenvironment through STAT3-mediated suppression of regulatory B-cell function and inhibition of the PD-1/PD-L1 pathway

Kondo, K., Shaim, H., Thompson, P. A., Burger, J. A., Keating, M. J., Estrov, Z. E., Harris, D., Kim, E., Ferrajoli, A., Daher, M., et al. (2017) · Leukemia · doi:10.1038/leu.2017.304 · Cited by 124

Recent updates in cancer immunotherapy: a comprehensive review and perspective of the 2018 China Cancer Immunotherapy Workshop in Beijing

Li, Z., Song, W., Rubinstein, M. P., & Liu, D. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0684-3 · Cited by 124

Pegilodecakin combined with pembrolizumab or nivolumab for patients with advanced solid tumours (IVY): a multicentre, multicohort, open-label, phase 1b trial

Naing, A., Wong, D. J. L., Infante, J. R., Korn, W. M., Aljumaily, R. M., Papadopoulos, K. P., Autio, K. A., Pant, S., Bauer, T. M., Drakaki, A., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30514-5 · Cited by 124

Gemogenovatucel-T (Vigil) immunotherapy as maintenance in frontline stage III/IV ovarian cancer (VITAL): a randomised, double-blind, placebo-controlled, phase 2b trial

Rocconi, R. P., Grosen, E. A., Ghamande, S. A., Chan, J. K., Barve, M. A., Oh, J., Tewari, D. S., Morris, P. C., Stevens, E., Bottsford-Miller, J. N., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30533-7 · Cited by 124

TGF-beta attenuates the class II transactivator and reveals an accessory pathway of IFN-γ action

Nandan, D., & Reiner, N. E. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.158.3.1095 · Cited by 121

Prospects for combined use of oncolytic viruses and CAR T-cells

Ajina, A., & Maher, J. F. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0294-6 · Cited by 120

Efficacy of chemotherapy or chemo‐anti‐PD‐1 combination after failed anti‐PD‐1 therapy for relapsed and refractory hodgkin lymphoma: A series from lysa centers

Rossi, C., Gilhodes, J., Maerevoet, M., Herbaux, C., Morschhauser, F., Brice, P., Garciaz, S., Borel, C., Ysebaert, L., Obéric, L., et al. (2018) · American Journal of Hematology · doi:10.1002/ajh.25154 · Cited by 119

Safety and Efficacy of PD‐1/PD‐L1 inhibitors combined with radiotherapy in patients with non‐small‐cell lung cancer: a systematic review and meta‐analysis

Geng, Y., Zhang, Q., Feng, S., Li, C., Wang, L., Zhao, X., Yang, Z., Li, Z., Luo, H., Liu, R., et al. (2021) · Cancer Medicine · doi:10.1002/cam4.3718 · Cited by 118

Natural killer cell-based immunotherapy for acute myeloid leukemia

Xu, J., & Niu, T. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00996-x · Cited by 115

A phase 1b study of dual PD-1 and CTLA-4 or KIR blockade in patients with relapsed/refractory lymphoid malignancies

Armand, P. A., Lesokhin, A. M., Borrello, I., Timmerman, J. M., Gutierrez, M. E., Zhu, L., McKiver, M. P., & Ansell, S. M. (2020) · Leukemia · doi:10.1038/s41375-020-0939-1 · Cited by 113

Surface Expression of TGFβ Docking Receptor GARP Promotes Oncogenesis and Immune Tolerance in Breast Cancer

Metelli, A., Wu, B. X., Fugle, C. W., Rachidi, S., Sun, S., Zhang, Y., Wu, J. D., Tomlinson, S., Howe, P. H., Yang, Y., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-1456 · Cited by 111

Genomic Profiling of Patient-Derived Xenografts for Lung Cancer Identifies B2M Inactivation Impairing Immunorecognition

Pereira, C. A., Giménez‐Xavier, P., Pros, E., Pajares, M. J., Moro, M., Gómez, A., Navarro, A., Condom, E., Morán, S., Goméz-López, G., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1946 · Cited by 111

Development of CAR T cells designed to improve antitumor efficacy and safety

Jaspers, J. E., & Brentjens, R. J. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.03.012 · Cited by 111

The Narrow-Spectrum HDAC Inhibitor Entinostat Enhances NKG2D Expression Without NK Cell Toxicity, Leading to Enhanced Recognition of Cancer Cells

Zhu, S., Denman, C. J., Cobanoglu, Z. S., Kiany, S., Lau, C. C., Gottschalk, S. M., Hughes, D. P. M., Kleinerman, E. S., & Lee, D. A. (2013) · Pharmaceutical Research · doi:10.1007/s11095-013-1231-0 · Cited by 110

Novel theranostic nanoporphyrins for photodynamic diagnosis and trimodal therapy for bladder cancer

Lin, T., Li, Y., Liu, Q., Chen, J.-L., Zhang, H., Lac, D., Zhang, H., Ferrara, K. W., Wachsmann‐Hogiu, S., Li, T., et al. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.07.026 · Cited by 107

Immune system in cancer radiotherapy: Resistance mechanisms and therapy perspectives

Mortezaee, K., & Najafi, M. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.103180 · Cited by 107

Radiation‐induced loss of cell surface CD47 enhances immune‐mediated clearance of human papillomavirus‐positive cancer

Vermeer, D. W., Spanos, W. C., Vermeer, P. D., Bruns, A. M., Lee, K. M., & Lee, J. H. (2013) · International Journal of Cancer · doi:10.1002/ijc.28015 · Cited by 104

Improving antitumor efficacy via combinatorial regimens of oncolytic virotherapy

Zhang, B., & Cheng, P. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01275-6 · Cited by 102

The efficacy and safety of combination of PD-1 and CTLA-4 inhibitors: a meta-analysis

Wu, K., Yi, M., Qin, S., Chu, Q., Zheng, X., & Wu, K. (2019) · Experimental Hematology & Oncology · doi:10.1186/s40164-019-0150-0 · Cited by 96

Development and Characterization of Bladder Cancer Patient-Derived Xenografts for Molecularly Guided Targeted Therapy

Pan, C.-X., Zhang, H., Tepper, C. G., Lin, T., Davis, R. R., Keck, J., Ghosh, P., Gill, P. S., Airhart, S. D., Bult, C., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0134346 · Cited by 94

Engineering better chimeric antigen receptor T cells

Zhang, H., Zhao, P., & Huang, H. (2020) · Experimental Hematology & Oncology · doi:10.1186/s40164-020-00190-2 · Cited by 93

Surface antigens analysis reveals significant expression of candidate targets for immunotherapy in adult acute lymphoid leukemia

Piccaluga, P. P., Arpinati, M., Candoni, A., Laterza, C., Paolini, S., Gazzola, A., Sabattini, E., Visani, G., & Pileri, S. A. (2010) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2010.529206 · Cited by 92

PI3Kα/δ inhibition promotes anti-tumor immunity through direct enhancement of effector CD8+ T-cell activity

Carnevalli, L. S., Sinclair, C., Taylor, M. A., Gutierrez, P. M., Langdon, S. A., Coenen-Stass, A. M. L., Mooney, L. M., Hughes, A. M., Jarvis, L., Staniszewska, A. D., et al. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0457-0 · Cited by 90

Human regulatory T cells lack the cyclophosphamide‐extruding transporter ABCB 1 and are more susceptible to cyclophosphamide‐induced apoptosis

Dimeloe, S., Frick, C., Fischer, M., Gubser, P. M., Razik, L., Bantug, G. R., Ravon, M., Langenkamp, A., & Hess, C. (2014) · European Journal of Immunology · doi:10.1002/eji.201444879 · Cited by 89

Cutting Edge: Vascular Endothelial Growth Factor-Mediated Signaling in Human CD45RO+ CD4+ T Cells Promotes Akt and ERK Activation and Costimulates IFN-γ Production

Basu, A., Hoerning, A., Datta, D. B., Edelbauer, M., Stack, M. P., Calzadilla, K., Pal, S., & Briscoe, D. M. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0900397 · Cited by 88

Nanoparticles to Improve the Efficacy of Peptide-Based Cancer Vaccines

Tornesello, A. L., Tagliamonte, M., Tornesello, M. L., Buonaguro, F. M., & Buonaguro, L. (2020) · Cancers · doi:10.3390/cancers12041049 · Cited by 85

Mechanisms underlying CD19-positive ALL relapse after anti-CD19 CAR T cell therapy and associated strategies

Nie, Y., Lu, W., Chen, D., Tu, H., Guo, Z., Zhou, X., Li, M., Tu, S., & Li, Y. (2020) · Biomarker Research · doi:10.1186/s40364-020-00197-1 · Cited by 85

Lifting the innate immune barriers to antitumor immunity

Rothlin, C. V., & Ghosh, S. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000695 · Cited by 83

MART-1 peptide vaccination plus IMP321 (LAG-3Ig fusion protein) in patients receiving autologous PBMCs after lymphodepletion: results of a Phase I trial

Romano, E., Michielin, O. A., Voelter, V., Laurent, J., Bichat, H., Stravodimou, A., Romero, P. J., Speiser, D. E., Triebel, F., Leyvraz, S., et al. (2014) · Journal of Translational Medicine · doi:10.1186/1479-5876-12-97 · Cited by 82

Radiotherapy and cGAS/STING signaling: Impact on MDSCs in the tumor microenvironment

Kho, V. M., Mekers, V. E., Span, P. N., Bussink, J., & Adema, G. J. (2021) · Cellular Immunology · doi:10.1016/j.cellimm.2021.104298 · Cited by 82

Unraveling Cancer Chemoimmunotherapy Mechanisms by Gene and Protein Expression Profiling of Responses to Cyclophosphamide

Moschella, F., Valentini, M., Aricò, E., Macchia, I., Sestili, P., D’Urso, M. T., Alessandri, C., Belardelli, F., & Proietti, E. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-4523 · Cited by 81

A Novel Fusion of ALT-803 (Interleukin (IL)-15 Superagonist) with an Antibody Demonstrates Antigen-specific Antitumor Responses

Liu, B., Kong, L., Han, K., Hong, H., Marcus, W. D., Chen, X., Jeng, E. K., Alter, S., Zhu, X., Rubinstein, M. P., et al. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.733600 · Cited by 79

CCL28 promotes breast cancer growth and metastasis through MAPK-mediated cellular anti-apoptosis and pro-metastasis

Yang, X. L., Liu, K. Y., Lin, F. J., Shi, H. M., & Ou, Z. L. (2017) · Oncology Reports · doi:10.3892/or.2017.5798 · Cited by 76

Efficacy of Humanized CD19-Targeted Chimeric Antigen Receptor (CAR)-Modified T Cells in Children and Young Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia

Maude, S. L., Barrett, D. M., Rheingold, S. R., Aplenc, R., Teachey, D. T., Callahan, C. A., Baniewicz, D., White, C., Talekar, M. K., Shaw, P. A., et al. (2016) · Blood · doi:10.1182/blood.v128.22.217.217 · Cited by 76

Ibrutinib treatment inhibits breast cancer progression and metastasis by inducing conversion of myeloid-derived suppressor cells to dendritic cells

Varikuti, S., Singh, B., Volpedo, G., Ahirwar, D. K., Jha, B. K., Saljoughian, N., Viana, A. G., Verma, C., Hamza, O., Halsey, G., et al. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-0743-8 · Cited by 76

Gr‐1+CD11b+ cells are responsible for tumor promoting effect of TGF‐β in breast cancer progression

Li, Z., Pang, Y., Gara, S. K., Achyut, B. R., Heger, C. D., Goldsmith, P. K., Lonning, S. M., & Yang, H. H. (2012) · International Journal of Cancer · doi:10.1002/ijc.27572 · Cited by 75

Th17 cells inhibit CD8+ T cell migration by systematically downregulating CXCR3 expression via IL-17A/STAT3 in advanced-stage colorectal cancer patients

Wang, D., Yu, W., Lian, J., Wu, Q., Liu, S., Yang, L., Li, F., Huang, L. J., Chen, X., Zhang, Z., et al. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00897-z · Cited by 75

Combined Vaccination with NY-ESO-1 Protein, Poly-ICLC, and Montanide Improves Humoral and Cellular Immune Responses in Patients with High-Risk Melanoma

Pavlick, A. C., Blazquez, A. B., Meseck, M. L., Lattanzi, M. W., Ott, P. A., Marron, T. U., Holman, R. M., Mandeli, J., Salazar, A. Μ., McClain, C. B., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0545 · Cited by 74

Current status of multiple antigen-presenting peptide vaccine systems: Application of organic and inorganic nanoparticles

Fujita, Y., & Taguchi, H. (2011) · Chemistry Central Journal · doi:10.1186/1752-153x-5-48 · Cited by 72

Carbon-ion beams induce production of an immune mediator protein, high mobility group box 1, at levels comparable with X-ray irradiation

Yoshimoto, Y., Oike, T., Okonogi, N., Suzuki, Y., Ando, K., Sato, H., Noda, S.-E., Isono, M., Mimura, K., Kono, K., et al. (2015) · Journal of Radiation Research · doi:10.1093/jrr/rrv007 · Cited by 72

Immunoassayable insulin in carcinoma of the cervix associated with hypoglycemia

Kiang, D. T., Bauer, G. E., & Kennedy, B. J. (1973) · Cancer · doi:10.1002/1097-0142(197304)31:4 · Cited by 71

CCR7 Mediates Inflammation-Associated Tumor Progression

Mburu, Y. K., Wang, J., Wood, M. A., Walker, W. H., & Ferris, R. L. (2006) · Immunologic Research · doi:10.1385/ir:36:1:61 · Cited by 70

GARP Dampens Cancer Immunity by Sustaining Function and Accumulation of Regulatory T Cells in the Colon

Salem, M., Wallace, C. H., Velegraki, M., Li, A., Ansa-Addo, E. A., Metelli, A., Kwon, H., Riesenberg, B., Wu, B. X., Zhang, Y., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-2623 · Cited by 69

Gemcitabine alters the proteasome composition and immunopeptidome of tumour cells

Gravett, A. M., Trautwein, N., Stevanović, S., Dalgleish, A. G., & Copier, J. P. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1438107 · Cited by 68

Tertiary Lymphoid Organs in Cancer Immunology: Mechanisms and the New Strategy for Immunotherapy

Lin, L., Hu, X., Zhang, H., & Hu, H. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01398 · Cited by 63

Activin A Promotes Regulatory T-cell–Mediated Immunosuppression in Irradiated Breast Cancer

Martino, M. D., Daviaud, C., Diamond, J. M., Kraynak, J., Alard, A., Formenti, S. C., Miller, L. D., Demaria, S., & Vanpouille‐Box, C. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0305 · Cited by 62

Phosphoinositide 3-kinase signaling can modulate MHC class I and II expression

Chandrasekaran, S., Sasaki, M., Scharer, C. D., Kissick, H. T., Patterson, D. G., Magliocca, K. R., Seykora, J. T., Sapkota, B., Gutman, D. A., Cooper, L. A., et al. (2019) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-19-0545 · Cited by 61

Tolerability and safety of EUS-injected adenovirus-mediated double-suicide gene therapy with chemotherapy in locally advanced pancreatic cancer: a phase 1 trial

Lee, J.-C., Shin, D. W., Park, H., Kim, J., Youn, Y., Kim, J. H., Kim, J., & Hwang, J. (2020) · Gastrointestinal Endoscopy · doi:10.1016/j.gie.2020.02.012 · Cited by 60

Antagonistic anti-LILRB1 monoclonal antibody regulates antitumor functions of natural killer cells

Chen, H., Chen, Y., Deng, M., John, S., Gui, X., Kansagra, A. J., Chen, W., Kim, J., Lewis, C. M., Wu, G., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000515 · Cited by 60

Optimal induction of HPV DNA vaccine-induced CD8+ T cell responses and therapeutic antitumor effect by antigen engineering and electroporation

Seo, S. H., Jin, H., Park, S. H., Youn, J. I., & Sung, Y. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.07.033 · Cited by 56

Blockade of TGF-β signaling: a potential target for cancer immunotherapy?

Ungefroren, H. (2019) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2019.1636034 · Cited by 53

The Phosphatidylinositol 3-kinase Pathway as a Potential Therapeutic Target in Bladder Cancer

Zeng, S.-X., Zhu, Y., Ma, A.-H., Yu, W., Zhang, H.-Y., Lin, T., Shi, W., Tepper, C., Henderson, P., Airhart, S., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0033 · Cited by 52

The effects of radiation on angiogenesis

Grabham, P. W., & Sharma, P. M. (2013) · Vascular Cell · doi:10.1186/2045-824x-5-19 · Cited by 50

High CXC Chemokine Ligand 16 (CXCL16) Expression Promotes Proliferation and Metastasis of Lung Cancer via Regulating the NF-κB Pathway

Liang, K., Liu, Y., Dun, E., JingBin, L., Yang, F., & Hu, K. (2018) · Medical Science Monitor · doi:10.12659/msm.906230 · Cited by 49

Type I Interferon Response in Radiation-Induced Anti-Tumor Immunity

Zhang, F., Manna, S., Pop, L. M., Chen, Z. J., Fu, Y., & Hannan, R. (2020) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2019.12.009 · Cited by 44

Antibody targeting tumor-derived soluble NKG2D ligand sMIC reprograms NK cell homeostatic survival and function and enhances melanoma response to PDL1 blockade therapy

Basher, F., Dhar, P., Wang, X., Wainwright, D. A., Zhang, B., Sosman, J. A., Ji, Z., & Wu, J. D. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00896-0 · Cited by 44

Tumor-Targeting Multifunctional Micelles for Imaging and Chemotherapy of Advanced Bladder Cancer

Lin, T., Li, Y.-P., Zhang, H., Luo, J., Goodwin, N. C., Gao, T., White, R. D., Lam, K. S., & Pan, C.-X. (2012) · Nanomedicine · doi:10.2217/nnm.12.150 · Cited by 42

Safety, PK/PD, and anti-tumor activity of RO6874281, an engineered variant of interleukin-2 (IL-2v) targeted to tumor-associated fibroblasts via binding to fibroblast activation protein (FAP).

Mau‐Sørensen, M., Ros, W., Rodriguez-Ruiz, M. E., Robbrecht, D. G. J., Rohrberg, K. S., Martín-Liberal, J., Lassen, U., Melero, I., Lolkema, M. P., Tabernero, J. M., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.e15155 · Cited by 42

Polymorphonuclear-MDSCs Facilitate Tumor Regrowth After Radiation by Suppressing CD8+ T Cells

Zhang, J., Zhang, L., Yang, Y., Liu, Q., Ma, H., Huang, A., Zhao, Y., Xia, Z., Liu, T., & Wu, G. (2020) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2020.11.038 · Cited by 42

Impact of MET alterations on targeted therapy with EGFR-tyrosine kinase inhibitors for EGFR-mutant lung cancer

Zhang, Z., Yang, S., & Wang, Q. (2019) · Biomarker Research · doi:10.1186/s40364-019-0179-6 · Cited by 35

Genomic Profiling of Patient-Derived Xenografts for Lung Cancer Identifies B2M Inactivation Impairing Immunorecognition

Pereira, C. A., Giménez‐Xavier, P., Pros, E., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1946-t · Cited by 34

CCR7 as a novel therapeutic target in t-cell PROLYMPHOCYTIC leukemia

Cuesta‐Mateos, C., Fuentes, P., Schrader, A., Juárez-Sánchez, R., Loscertales, J., Mateu‐Albero, T., Vega‐Piris, L., Espartero‐Santos, M., Marcos‐Jiménez, A., Sánchez-López, B. A., et al. (2020) · Biomarker Research · doi:10.1186/s40364-020-00234-z · Cited by 32

Image-guided photo-therapeutic nanoporphyrin synergized HSP90 inhibitor in patient-derived xenograft bladder cancer model

Long, Q., Lin, T., Huang, Y., Li, X., Ma, A., Zhang, H., Carney, R. P., Airhart, S. D., Lam, K. S., White, R. D., et al. (2018) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2017.12.014 · Cited by 31

Tumor infiltration by chemokine receptor 7 (CCR7)+T-lymphocytes is a favorable prognostic factor in metastatic colorectal cancer

Correale, P., Rotundo, M. S., Botta, C., Vecchio, M. T. D., Tassone, P., & Tagliaferri, P. (2012) · OncoImmunology · doi:10.4161/onci.19404 · Cited by 29

Combination of cyclin-dependent kinase and immune checkpoint inhibitors for the treatment of bladder cancer

Long, Q., Ma, A., Zhang, H., Cao, Z., Xia, R., Lin, T., Sonpavde, G., White, R. D., Guo, J., & Pan, C.-X. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02609-5 · Cited by 17

Prospects and progress ofListeria-based cancer vaccines

Bolhassani, A., Naderi, N., & Soleymani, S. (2017) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2017.1366446 · Cited by 16

The Association of Radiation Dose-Fractionation and Immunotherapy Use With Overall Survival in Metastatic Melanoma Patients

Wang, S.-J., Jhawar, S. R., Rivera‐Núñez, Z., Silk, A. W., Byun, J., Miller, E. D., Blakaj, D. M., Parikh, R. R., Weiner, J., & Goyal, S. (2020) · Cureus · doi:10.7759/cureus.8767 · Cited by 15

[On the the terminations of afferent nerve fibers in the lumbosacral region of the spinal cord].

Al, M. (1965) · PubMed · Cited by 13

Nanomicelle Formulation Modifies The Pharmacokinetic Profiles and Cardiac Toxicity of Daunorubicin

Zhang, H., Li, Y., Lin, T., Xiao, K., Haddad, A. S., Henderson, P. T., Jonas, B. A., Chen, M., Xiao, W., Liu, R., et al. (2014) · Nanomedicine · doi:10.2217/nnm.14.44 · Cited by 10

Alessandro Moretta 1953–2018

Moretta, L., & Mantovani, A. (2018) · Nature Immunology · doi:10.1038/s41590-018-0075-5 · Cited by 2

Combination strategies with PD-1/PD-L1 blockade: current advances and future directions

Yi, M., Zheng, X., Niu, M., Zhu, S., Ge, H., & Wu, K. (2022) · Molecular Cancer · doi:10.1186/s12943-021-01489-2 · Cited by 1,445

Neoantigens: promising targets for cancer therapy

Xie, N., Shen, G., Gao, W., Huang, Z., Huang, C., & Fu, L. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01270-x · Cited by 1,020

Cold and hot tumors: from molecular mechanisms to targeted therapy

Wu, B., Zhang, B., Li, B., Wu, H., & Jiang, M. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01979-x · Cited by 811

Evolving therapeutic landscape of advanced hepatocellular carcinoma

Yang, C. G., Zhang, H., Zhang, L., Zhu, A. X., Bernards, R., Qin, W., & Wang, C. (2022) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-022-00704-9 · Cited by 747

CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy

Pan, K., Farrukh, H., Chittepu, V. C. S. R., Xu, H., Pan, C.-X., & Zhu, Z. G. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02327-z · Cited by 685

Checkpoint inhibitors in cancer Immunotherapy: Mechanisms, Resistance, and Combination Strategies

Shah, R. K., Raval, Y., Shaikh, M., Hadiya, J., Hirpara, F., Makwana, S., & Tirgar, P. (2026) · Springer Link (Chiba Institute of Technology) · doi:10.1051/epjconf/202634801013/pdf

Cancer immunotherapy: Strategies for personalization and combinatorial approaches

Sathyanarayanan, V., & Neelapu, S. S. (2015) · Molecular Oncology · doi:10.1016/j.molonc.2015.10.009 · Cited by 110

Combining Immune Checkpoint Inhibitors With Conventional Cancer Therapy

Yan, Y., Kumar, A. B., Finnes, H. D., Markovic, S. N., Park, S. S., Dronca, R. S., & Dong, H. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01739 · Cited by 231

Lessons learned from the blockade of immune checkpoints in cancer immunotherapy

Li, X., Shao, C., Shi, Y., & Han, W. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0578-4 · Cited by 389

Combinations using checkpoint blockade to overcome resistance

Morganti, S., & Curigliano, G. (2020) · ecancermedicalscience · doi:10.3332/ecancer.2020.1148 · Cited by 25